Pfizer has completed its approximately $7 billion acquisition of biotech firm Metsera, acquiring a portfolio of anti-obesity and cardio-metabolic disease drugs. The transaction included a payment of $65.60 in cash per share plus contingent rights of up to $20.65 per share upon achievement of clinical and regulatory milestones. Metsera brought candidate MET-097i, an injectable GLP-1 receptor agonist with weekly and monthly administration, which in Phase II achieved weight reduction of 11.3% over 12 weeks with limited adverse effects. Another candidate, MET-233i, is a monthly phase I amylin analog, tested both as monotherapy and in combination with MET-097i, where 36 days of amylin monotherapy resulted in 8.4% placebo-corrected weight loss. Pfizer plans to launch ten phase III studies for PF-3944 (MET-097i) this year after stopping its own danuglipron in April 2025 due to elevated liver enzymes. CEO Albert Bourla said at the 2026 JP Morgan Healthcare Conference that the phase II data for ultra-long-acting GLP-1 is very encouraging and he expects the therapies to be on the market by 2028. The anti-obesity drug market is estimated to reach $150 billion by 2030.[1][2][3][4][6]